The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment

Julie E. Oomens; Sarah A. Biber; Marilyn Albert; Michael L. Alosco; Konstantinos Arfanakis; Tammie L.S. Benzinger; James B. Brewer; Jeffrey M. Burns; Erin Chin; Nathaniel A. Chin; Lindsay R. Clark; Ann D. Cohen; Jeffrey L. Dage; John A. Detre; Bradford C. Dickerson; Frank P. DiFilippo; Michael C. Donohue; Christopher H. van Dyck; Audrey P. Fan; Thomas J. Grabowski; Mohamad Habes; Theresa M. Harrison; Trey Hedden; Timothy J. Hohman; William J. Jagust; Angela L. Jefferson; Gregory A. Jicha; Steven R. Kecskemeti; Kejal Kantarci; Dirk C. Keene; Janice E. Knoefel; Walter A. Kukull; Weili Lin; Patrick Lao; Rebecca J. Lepping; Swati R. Levendovszky; Arjun V. Masurkar; Jonathan E. McConathy; Monica Rivera-Mindt; Darby J. Morhardt; Douglas C. Noll; Ozioma C. Okonkwo; Todd B. Parrish; Gil D. Rabinovici; Annalise Rahman-Filipiak; Eric M. Reiman; Shannon L. Risacher; Howie Rosen; Marc D. Rudolph; Lon S. Schneider; Lisa C. Silbert; Allen W. Song; Craig E.L. Stark; Russel H. Swerdlow; Paul M. Thompson; David Vaillancourt; Victor L. Villemagne; David A. Wolk; Deqiang Qiu; Tatiana M. Foroud; Sterling C. Johnson; Elizabeth C. Mormino

doi:10.1002/alz.70880

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment

Julie E. Oomens
, Sarah A. Biber
, Marilyn Albert
, Michael L. Alosco
, Konstantinos Arfanakis
, Tammie L.S. Benzinger
, James B. Brewer
, Jeffrey M. Burns
, Erin Chin
, Nathaniel A. Chin
, Lindsay R. Clark
, Ann D. Cohen
, Jeffrey L. Dage
, John A. Detre
, Bradford C. Dickerson
, Frank P. DiFilippo
, Michael C. Donohue
, Christopher H. van Dyck
, Audrey P. Fan
, Thomas J. Grabowski

Mohamad Habes, Theresa M. Harrison, Trey Hedden, Timothy J. Hohman, William J. Jagust, Angela L. Jefferson, Gregory A. Jicha, Steven R. Kecskemeti, Kejal Kantarci, Dirk C. Keene, Janice E. Knoefel, Walter A. Kukull, Weili Lin, Patrick Lao, Rebecca J. Lepping, Swati R. Levendovszky, Arjun V. Masurkar, Jonathan E. McConathy, Monica Rivera-Mindt, Darby J. Morhardt, Douglas C. Noll, Ozioma C. Okonkwo, Todd B. Parrish, Gil D. Rabinovici, Annalise Rahman-Filipiak, Eric M. Reiman, Shannon L. Risacher, Howie Rosen, Marc D. Rudolph, Lon S. Schneider, Lisa C. Silbert, Allen W. Song, Craig E.L. Stark, Russel H. Swerdlow, Paul M. Thompson, David Vaillancourt, Victor L. Villemagne, David A. Wolk, Deqiang Qiu, Tatiana M. Foroud, Sterling C. Johnson, Elizabeth C. Mormino

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI. METHODS: We developed and distributed a survey capturing information on the 36 CLARiTI site's theme/expertise, recruitment plans, and the intersection of CLARiTI with other ADRC imaging efforts. RESULTS: Anticipated CLARiTI enrollees spanned 11 different categories of suspected etiologies underlying impairment. A wide range of risk factors were endorsed across sites regarding the enrollment of unimpaired individuals. Variability also existed regarding site-level strategies in enrollment into CLARiTI versus other imaging efforts. DISCUSSION: We anticipate that the 2000 individuals that will enroll into CLARiTI will reflect the clinical heterogeneity already in place across the ADRC network. Highlights: The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will leverage and contribute to the existing Alzheimer's Disease Research Centers (ADRC) program by supporting standardized imaging and plasma collection across all centers. We summarize the variation in scientific focus and enrollment plans across ADRC sites participating in CLARiTI. The anticipated CLARiTI cohort will reflect the clinical heterogeneity that already exists across the ADRC network. CLARiTI will contribute to scientific goals related to the detection of multi-etiological signatures relevant for Alzheimer's disease and related disorders (ADRDs).

Original language	English
Article number	e70880
Journal	Alzheimer's and Dementia
Volume	21
Issue number	11
DOIs	https://doi.org/10.1002/alz.70880
State	Published - Nov 2025

Bibliographical note

Publisher Copyright:
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Funding

All authors receive funding from the NIH. Additionally, E.C.M. receives funding from the Alzheimer's Association, Simons Foundation, and Archer Foundation; and has been a consultant for Eli Lilly, Biogen, Roche, and Alector. D.A.W. receives funding from Biogen and consulting fees or honoraria from Qynapse, Eli Lilly, Functional Neuromodulation, and GSK. V.L.V. receives funding from Piramal Imaging. H.R. receives funding from Biogen, and consulting fees from Wave Neuroscience, Ionis Pharmaceuticals, Eisai Pharmaceuticals, and Genentech. G.D.R. received funding from Alzheimer's Association, the American College of Radiology, Eli Lilly, Life Molecular Imaging, GE Healthcare, Genentech, and the Rainwater Charitable Foundation; consultant fees from Eli Lilly, GE Healthcare, Roche, Genentech, and Alector. S.R.L. receives consulting fees from Applied Cognition. J.E.M. receives research support from Eli Lilly/Avid, GE Healthcare, Novartis and Cytosite Biopharma; consultant fees from Eli Lilly/AVID, GE Healthcare, Novartis, and Telix, and honoraria from Telix. W.J.J. receives funding from Alzheimer's Association and Roche/Genentech; and consultant fees from Eisai and Lilly. T.J.H. served on an advisory board for Vivid Genomics. M.C.D. receives funding from Eli Lilly and Eisai; and consulting fees from Roche. B.C.D. receives consulting fees from Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Takeda, and Wave LifeSciences. J.L.D. is an inventor on patents or patent applications assigned to Eli Lilly and Company relating to the assays, methods, reagents and / or compositions of matter for P‐tau assays and Aβ targeting therapeutics. J.L.D. has/is served/serving as a consultant or on advisory boards for Eisai, Abbvie, Genotix Biotechnologies Inc, Gates Ventures, Gate Neurosciences, Dolby Family Ventures, Karuna Therapeutics, Alzheimer's Disease Drug Discovery Foundation, AlzPath Inc., Cognito Therapeutics, Inc., Eli Lilly and Company, Prevail Therapeutics, Neurogen Biomarking, Spear Bio, Rush University, University of Kentucky, Tymora Analytical Operations, MindImmune Therapeutics, Inc, Early is Good, and Quanterix. J.L.D. has received research support from ADx Neurosciences, Fujirebio, Roche Diagnostics and Eli Lilly and Company in the past two years. J.L.D. has received speaker fees from Eli Lilly and Company and LabCorp. J.L.D. is a founder and advisor for Monument Biosciences and Dage Scientific LLC. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, MindImmune Therapeutics Inc., AlzPath Inc., Neurogen Biomarking, and Monument Biosciences. S.C.J. receives consulting fees from Enigma and Alzpath. W.A.K. is Associate Editor for A&D TRCI and on the editorial boards of JAGS, and AD&AD; received NIH grants; serves on advisory boards for BU, KU, ISMMS and ADRCs. K.K. receives funding from NIH; was funded by the ADDF and received research support form Eli Lilly; consults for Biogen, Eisai, and BioArctic; and is supported by an endowed professorship from the Katherine B. Andersen Foundation. M.L.A. receives honararium from the Michael J. Fox Foundation; receives research funding from Life Molecular Imaging Inc.; and receives royalties from Oxford University Press Inc. Author disclosures are available in the supporting information . This work was funded by the National Institutes of Health (U01‐AG082350). Funding sources did not have any role in study design or decisions related to publication.

Funders	Funder number
American College of Radiology
Life Molecular Imaging Inc.
Alzheimer's Association and Roche
Roche
Archer Foundation
Rainwater Charitable Foundation
Alzheimer's Association
Eisai
Genentech
NIH
ADDF
GE Healthcare
Eli Lilly
Piramal Imaging
Simons Foundation
Biogen IDEC
GSK
National Institutes of Health (NIH)	U01‐AG082350

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alzheimer's disease
biomarkers
magnetic resonance imaging
neuroimaging
pathology
plasma markers
positron emission tomography

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.70880

Cite this

Oomens, J. E., Biber, S. A., Albert, M., Alosco, M. L., Arfanakis, K., Benzinger, T. L. S., Brewer, J. B., Burns, J. M., Chin, E., Chin, N. A., Clark, L. R., Cohen, A. D., Dage, J. L., Detre, J. A., Dickerson, B. C., DiFilippo, F. P., Donohue, M. C., van Dyck, C. H., Fan, A. P., ... Mormino, E. C. (2025). The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment. Alzheimer's and Dementia, 21(11), Article e70880. https://doi.org/10.1002/alz.70880

@article{28e8910757ff45a6a3df346dcd357a16,

title = "The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment",

abstract = "INTRODUCTION: The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI. METHODS: We developed and distributed a survey capturing information on the 36 CLARiTI site's theme/expertise, recruitment plans, and the intersection of CLARiTI with other ADRC imaging efforts. RESULTS: Anticipated CLARiTI enrollees spanned 11 different categories of suspected etiologies underlying impairment. A wide range of risk factors were endorsed across sites regarding the enrollment of unimpaired individuals. Variability also existed regarding site-level strategies in enrollment into CLARiTI versus other imaging efforts. DISCUSSION: We anticipate that the 2000 individuals that will enroll into CLARiTI will reflect the clinical heterogeneity already in place across the ADRC network. Highlights: The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will leverage and contribute to the existing Alzheimer's Disease Research Centers (ADRC) program by supporting standardized imaging and plasma collection across all centers. We summarize the variation in scientific focus and enrollment plans across ADRC sites participating in CLARiTI. The anticipated CLARiTI cohort will reflect the clinical heterogeneity that already exists across the ADRC network. CLARiTI will contribute to scientific goals related to the detection of multi-etiological signatures relevant for Alzheimer's disease and related disorders (ADRDs).",

keywords = "Alzheimer's disease, biomarkers, magnetic resonance imaging, neuroimaging, pathology, plasma markers, positron emission tomography",

author = "Oomens, \{Julie E.\} and Biber, \{Sarah A.\} and Marilyn Albert and Alosco, \{Michael L.\} and Konstantinos Arfanakis and Benzinger, \{Tammie L.S.\} and Brewer, \{James B.\} and Burns, \{Jeffrey M.\} and Erin Chin and Chin, \{Nathaniel A.\} and Clark, \{Lindsay R.\} and Cohen, \{Ann D.\} and Dage, \{Jeffrey L.\} and Detre, \{John A.\} and Dickerson, \{Bradford C.\} and DiFilippo, \{Frank P.\} and Donohue, \{Michael C.\} and \{van Dyck\}, \{Christopher H.\} and Fan, \{Audrey P.\} and Grabowski, \{Thomas J.\} and Mohamad Habes and Harrison, \{Theresa M.\} and Trey Hedden and Hohman, \{Timothy J.\} and Jagust, \{William J.\} and Jefferson, \{Angela L.\} and Jicha, \{Gregory A.\} and Kecskemeti, \{Steven R.\} and Kejal Kantarci and Keene, \{Dirk C.\} and Knoefel, \{Janice E.\} and Kukull, \{Walter A.\} and Weili Lin and Patrick Lao and Lepping, \{Rebecca J.\} and Levendovszky, \{Swati R.\} and Masurkar, \{Arjun V.\} and McConathy, \{Jonathan E.\} and Monica Rivera-Mindt and Morhardt, \{Darby J.\} and Noll, \{Douglas C.\} and Okonkwo, \{Ozioma C.\} and Parrish, \{Todd B.\} and Rabinovici, \{Gil D.\} and Annalise Rahman-Filipiak and Reiman, \{Eric M.\} and Risacher, \{Shannon L.\} and Howie Rosen and Rudolph, \{Marc D.\} and Schneider, \{Lon S.\} and Silbert, \{Lisa C.\} and Song, \{Allen W.\} and Stark, \{Craig E.L.\} and Swerdlow, \{Russel H.\} and Thompson, \{Paul M.\} and David Vaillancourt and Villemagne, \{Victor L.\} and Wolk, \{David A.\} and Deqiang Qiu and Foroud, \{Tatiana M.\} and Johnson, \{Sterling C.\} and Mormino, \{Elizabeth C.\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Alzheimer's \& Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2025",

month = nov,

doi = "10.1002/alz.70880",

language = "English",

volume = "21",

number = "11",

}

Oomens, JE, Biber, SA, Albert, M, Alosco, ML, Arfanakis, K, Benzinger, TLS, Brewer, JB, Burns, JM, Chin, E, Chin, NA, Clark, LR, Cohen, AD, Dage, JL, Detre, JA, Dickerson, BC, DiFilippo, FP, Donohue, MC, van Dyck, CH, Fan, AP, Grabowski, TJ, Habes, M, Harrison, TM, Hedden, T, Hohman, TJ, Jagust, WJ, Jefferson, AL, Jicha, GA, Kecskemeti, SR, Kantarci, K, Keene, DC, Knoefel, JE, Kukull, WA, Lin, W, Lao, P, Lepping, RJ, Levendovszky, SR, Masurkar, AV, McConathy, JE, Rivera-Mindt, M, Morhardt, DJ, Noll, DC, Okonkwo, OC, Parrish, TB, Rabinovici, GD, Rahman-Filipiak, A, Reiman, EM, Risacher, SL, Rosen, H, Rudolph, MD, Schneider, LS, Silbert, LC, Song, AW, Stark, CEL, Swerdlow, RH, Thompson, PM, Vaillancourt, D, Villemagne, VL, Wolk, DA, Qiu, D, Foroud, TM, Johnson, SC & Mormino, EC 2025, 'The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment', Alzheimer's and Dementia, vol. 21, no. 11, e70880. https://doi.org/10.1002/alz.70880

TY - JOUR

T1 - The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)

T2 - Overview of consortium sites and anticipated enrollment

AU - Oomens, Julie E.

AU - Biber, Sarah A.

AU - Albert, Marilyn

AU - Alosco, Michael L.

AU - Arfanakis, Konstantinos

AU - Benzinger, Tammie L.S.

AU - Brewer, James B.

AU - Burns, Jeffrey M.

AU - Chin, Erin

AU - Chin, Nathaniel A.

AU - Clark, Lindsay R.

AU - Cohen, Ann D.

AU - Dage, Jeffrey L.

AU - Detre, John A.

AU - Dickerson, Bradford C.

AU - DiFilippo, Frank P.

AU - Donohue, Michael C.

AU - van Dyck, Christopher H.

AU - Fan, Audrey P.

AU - Grabowski, Thomas J.

AU - Habes, Mohamad

AU - Harrison, Theresa M.

AU - Hedden, Trey

AU - Hohman, Timothy J.

AU - Jagust, William J.

AU - Jefferson, Angela L.

AU - Jicha, Gregory A.

AU - Kecskemeti, Steven R.

AU - Kantarci, Kejal

AU - Keene, Dirk C.

AU - Knoefel, Janice E.

AU - Kukull, Walter A.

AU - Lin, Weili

AU - Lao, Patrick

AU - Lepping, Rebecca J.

AU - Levendovszky, Swati R.

AU - Masurkar, Arjun V.

AU - McConathy, Jonathan E.

AU - Rivera-Mindt, Monica

AU - Morhardt, Darby J.

AU - Noll, Douglas C.

AU - Okonkwo, Ozioma C.

AU - Parrish, Todd B.

AU - Rabinovici, Gil D.

AU - Rahman-Filipiak, Annalise

AU - Reiman, Eric M.

AU - Risacher, Shannon L.

AU - Rosen, Howie

AU - Rudolph, Marc D.

AU - Schneider, Lon S.

AU - Silbert, Lisa C.

AU - Song, Allen W.

AU - Stark, Craig E.L.

AU - Swerdlow, Russel H.

AU - Thompson, Paul M.

AU - Vaillancourt, David

AU - Villemagne, Victor L.

AU - Wolk, David A.

AU - Qiu, Deqiang

AU - Foroud, Tatiana M.

AU - Johnson, Sterling C.

AU - Mormino, Elizabeth C.

PY - 2025/11

Y1 - 2025/11

N2 - INTRODUCTION: The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI. METHODS: We developed and distributed a survey capturing information on the 36 CLARiTI site's theme/expertise, recruitment plans, and the intersection of CLARiTI with other ADRC imaging efforts. RESULTS: Anticipated CLARiTI enrollees spanned 11 different categories of suspected etiologies underlying impairment. A wide range of risk factors were endorsed across sites regarding the enrollment of unimpaired individuals. Variability also existed regarding site-level strategies in enrollment into CLARiTI versus other imaging efforts. DISCUSSION: We anticipate that the 2000 individuals that will enroll into CLARiTI will reflect the clinical heterogeneity already in place across the ADRC network. Highlights: The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will leverage and contribute to the existing Alzheimer's Disease Research Centers (ADRC) program by supporting standardized imaging and plasma collection across all centers. We summarize the variation in scientific focus and enrollment plans across ADRC sites participating in CLARiTI. The anticipated CLARiTI cohort will reflect the clinical heterogeneity that already exists across the ADRC network. CLARiTI will contribute to scientific goals related to the detection of multi-etiological signatures relevant for Alzheimer's disease and related disorders (ADRDs).

AB - INTRODUCTION: The Consortium for Clarity in Alzheimer's disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer's Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI. METHODS: We developed and distributed a survey capturing information on the 36 CLARiTI site's theme/expertise, recruitment plans, and the intersection of CLARiTI with other ADRC imaging efforts. RESULTS: Anticipated CLARiTI enrollees spanned 11 different categories of suspected etiologies underlying impairment. A wide range of risk factors were endorsed across sites regarding the enrollment of unimpaired individuals. Variability also existed regarding site-level strategies in enrollment into CLARiTI versus other imaging efforts. DISCUSSION: We anticipate that the 2000 individuals that will enroll into CLARiTI will reflect the clinical heterogeneity already in place across the ADRC network. Highlights: The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) will leverage and contribute to the existing Alzheimer's Disease Research Centers (ADRC) program by supporting standardized imaging and plasma collection across all centers. We summarize the variation in scientific focus and enrollment plans across ADRC sites participating in CLARiTI. The anticipated CLARiTI cohort will reflect the clinical heterogeneity that already exists across the ADRC network. CLARiTI will contribute to scientific goals related to the detection of multi-etiological signatures relevant for Alzheimer's disease and related disorders (ADRDs).

KW - Alzheimer's disease

KW - biomarkers

KW - magnetic resonance imaging

KW - neuroimaging

KW - pathology

KW - plasma markers

KW - positron emission tomography

UR - https://www.scopus.com/pages/publications/105021200775

UR - https://www.scopus.com/pages/publications/105021200775#tab=citedBy

U2 - 10.1002/alz.70880

DO - 10.1002/alz.70880

M3 - Article

C2 - 41208739

AN - SCOPUS:105021200775

SN - 1552-5260

VL - 21

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 11

M1 - e70880

ER -

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI): Overview of consortium sites and anticipated enrollment

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this